Maria Palasis's most recent trade in Lyra Therapeutics Inc was a trade of 1,702 Common Stock done at an average price of $3.4 . Disclosure was reported to the exchange on Jan. 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyra Therapeutics Inc | Maria Palasis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.36 per share. | 06 Jan 2026 | 1,702 | 1,096,733 | - | 3.4 | 5,726 | Common Stock |
| Beta Bionics Inc | Maria Palasis | Director | Sale of securities on an exchange or to another person at price $ 29.33 per share. | 01 Dec 2025 | 906 | 8,935 | - | 29.3 | 26,570 | Common Stock |
| Beta Bionics Inc | Maria Palasis | Director | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 01 Dec 2025 | 500 | 8,435 | - | 30.0 | 14,982 | Common Stock |
| Beta Bionics Inc | Maria Palasis | Director | Sale of securities on an exchange or to another person at price $ 26.86 per share. | 31 Oct 2025 | 1,287 | 9,960 | - | 26.9 | 34,567 | Common Stock |
| Beta Bionics Inc | Maria Palasis | Director | Sale of securities on an exchange or to another person at price $ 27.45 per share. | 31 Oct 2025 | 119 | 9,841 | - | 27.5 | 3,267 | Common Stock |
| Lyra Therapeutics Inc | Maria Palasis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 3,667 | 7,333 | - | - | Employee Stock Option (right to buy) | |
| Lyra Therapeutics Inc | Maria Palasis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 8.91 per share. | 10 Jul 2025 | 1,565 | 1,098,435 | - | 8.9 | 13,944 | Common Stock |
| Beta Bionics Inc | Maria Palasis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2025 | 11,247 | 11,247 | - | 0 | Common Stock | |
| Beta Bionics Inc | Maria Palasis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 9,137 | 9,137 | - | - | Director Stock Option (right to buy) | |
| Lyra Therapeutics Inc | Maria Palasis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 183,333 | 183,333 | - | - | Employee Stock Option (right to buy) | |
| Lyra Therapeutics Inc | Maria Palasis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 300,000 | 300,000 | - | 0 | Common Stock | |
| Lyra Therapeutics Inc | Maria Palasis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2024 | 500,000 | 500,000 | - | - | Stock Option | |
| Lyra Therapeutics Inc | Maria Palasis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 150,000 | 150,000 | - | - | Stock Option | |
| Lyra Therapeutics Inc | Maria Palasis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 250,000 | 250,000 | - | - | Stock Option | |
| Lyra Therapeutics Inc | Maria Palasis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 175,000 | 175,000 | - | - | Stock Option | |
| Lyra Therapeutics Inc | Maria Palasis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2022 | 127,400 | 127,400 | - | - | Stock Option | |
| Lyra Therapeutics Inc | Maria Palasis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 120,000 | 120,000 | - | - | Stock Option |